Stanley Lipkowitz

Deep Vein Thrombosis-primed neutrophils reshape the brain microenvironment to promote brain metastasis

This study shows that deep vein thrombosis primes neutrophils to promote brain metastasis in triple-negative breast cancer by enhancing their recruitment and NET formation.

TR-107, a novel mitochondrial ClpP agonist, induces robust antitumor activity against preclinical models of adrenocortical carcinoma

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

Cell type-centric interaction networks define spatial architecture of intrahepatic cholangiocarcinoma

This study defines the spatial architecture of intrahepatic cholangiocarcinoma using single-cell spatial proteomics and a graph-based deep learning framework to identify multicellular spatial patterns and their association with patient outcomes.

Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers

This study shows that reducing Flotillin-2 increases T-DM1 internalization and cytotoxicity in HER2-amplified cancers by enhancing HER2 ubiquitination and internalization.

AI-Driven Spatial Transcriptomics Unlocks Large-Scale Breast Cancer Biomarker Discovery from Histopathology

Path2Space predicts spatial gene expression and tumor microenvironment from histopathology slides, identifying new breast cancer subgroups and improving biomarker prediction.

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers

This study shows TRAIL treatment of TNBC cells activates the NFKB2 pathway, leading to cytokine production that enhances neutrophil chemotaxis and immune suppression.

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

ENLIGHT predicts patient response to targeted and immunotherapies using tumor transcriptomes without prior treatment response data, showing better accuracy than existing transcriptomics-based signatures.